Can Bicara Therapeutics cover its short-term obligations?

Its current ratio is 13.85 — current assets exceed current liabilities.

Where does Bicara Therapeutics's balance sheet data come from?

Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Bicara Therapeutics BCAX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$323.46M-30.0%	$96.69M-80.3%	$171.67M-67.0%	$436.61M+114%	$462.07M—
Short-term investments	——	——	——	——	——
Prepaid expenses and other current assets	$5.16M-40.6%	$7.25M-43.4%	$7.21M+853%	$7.79M—	$8.69M—
Total current assets	$544.92M—	$422.05M—	$297.37M—	$444.39M—	——
Property and equipment, net	$346K—	$330K—	$135K—	$117K—	——
Operating lease right-of-use assets	$1.43M—	$1.7M—	$1.97M—	$2.24M—	——
Other non-current assets	$6.91M—	$6.91M—	$7.8M—	$6.84M—	——
Total assets	$553.6M—	$430.99M—	$424.69M—	$453.59M—	——
Accrued expenses	$1.91M—	$5.04M—	$3.99M—	$2.17M—	——
Operating lease liabilities, current	$1.14M—	$1.12M—	$1.1M—	$1.07M—	——
Security deposits	——	——	——	——	——
Total current liabilities	$39.34M—	$28.95M—	$21.03M—	$17.23M—	——
Operating lease liabilities, non-current	$301K—	$593K—	$880K—	$1.16M—	——
Operating Lease Liabilities (Total)	——	——	——	——	——
Total liabilities	$39.64M—	$29.54M—	$21.91M—	$18.39M—	——
Preferred stock	$0—	$0—	$0—	$0—	——
Common stock	500M—	500M—	500M—	500M—	——
Additional paid-in capital	$929.37M—	$760.17M—	$724.49M—	$720.44M—	——
Retained earnings	-$415.18M—	-$358.97M—	-$321.58M—	-$285.25M—	——
Accumulated other comprehensive income (loss)	——	——	——	——	——
Total stockholders' equity	$513.96M+12.0%	$401.45M-18.4%	$402.78M-21.0%	$435.2M+349%	$458.96M+387%
Total liabilities and stockholders' equity	$553.6M—	$430.99M—	$424.69M—	$453.59M—	——
Available-for-Sale Debt Securities - Amortized Cost	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	——	——	——	——	——
Short- term Investments	——	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$6.91M—	$6.91M—	$7.8M—	$6.84M—	——
Investments - Amortized Cost Basis	——	——	——	——	——
Net Investment in Lease	$1.43M—	$1.7M—	$1.97M—	$2.24M—	——
Investments and Cash	——	——	——	——	——
Operating lease right-of-use assets	$1.43M—	$1.7M—	$1.97M—	$2.24M—	——
Other non-current assets	$6.91M—	$6.91M—	$7.8M—	$6.84M—	——
Operating Lease Right-of-Use Assets in Other Assets	$1.43M—	$1.7M—	$1.97M—	$2.24M—	——
Software and Technology Licenses, Net	$6.91M—	$6.91M—	$7.8M—	$6.84M—	——
Accrued Manufacturing Costs	$1.91M—	$5.04M—	$3.99M—	$2.17M—	——
Compensation and benefits	$1.91M—	$5.04M—	$3.99M—	$2.17M—	——
Professional Service Fees Payable	$1.67M—	$591K—	$546K—	$478K—	——
Total debt	$1.44M—	$1.71M—	$1.98M—	$2.24M—	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	——	——	——	——	——
Common Stock Par Value Per Share	$0.00—	$0.00—	$0.00—	$0.00—	——
Common Stock Shares Issued	65.5M—	56.6M—	54.6M—	54.6M—	——
Common Stock Shares Outstanding	——	——	——	——	——
Convertible Preferred Stock Authorized Shares	10M—	10M—	10M—	10M—	——
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	——
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$8K—	$7K—	$7K—	$7K—	——
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	——
Investments - Gross Unrealized Losses	——	——	——	——	——
Number of Exercisable Options	——	——	——	——	——
Preferred Stock Par Value Per Share	$0.00—	$0.00—	$0.00—	$0.00—	——
Share-Based Payment Award Options Outstanding - Number	11.9M—	9.9M—	9.2M—	8.8M—	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Unrealized Gains on Investments	——	——	——	——	——
Unrealized Losses on Investments (Before Tax)	——	——	——	——	——
Weighted Average Exercise Price of Exercisable Options	——	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	$10.74—	$9.03—	$7.69—	$7.56—	——
Cumulative Cost Basis	——	——	——	——	——
Accrued manufacturing expenses	——	——	——	——	——
Professional service fees	$1.67M—	$591K—	$546K—	$478K—	——
Accrued research and development expenses	$13.52M—	$13.09M—	$10.33M—	$9.21M—	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	——	——	——	——	——
Gross Unrealized Gains	——	——	——	——	——
Total	——	——	——	——	——
Available for sale investments	——	——	——	——	——
Common stock, par value (in dollars per share)	$0—	$0—	$0—	$0—	——
Common stock, shares authorized (in shares)	$500M—	$500M—	$500M—	$500M—	——
Common stock, shares issued (in shares)	$65.55M—	$56.6M—	$54.61M—	$54.56M—	——
Common Stock, Shares, Outstanding	$65.55M—	$56.6M—	$54.61M—	$54.56M—	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	——	——	——	——	——
Less than 12 months	——	——	——	——	——
12 months or more	——	——	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	——	——	——	——	——
Number of securities held in unrealized loss position	——	——	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss	——	——	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	——	——	——	——	——
Cost not yet recognized	——	——	——	——	——
Area of land (in square feet)	——	——	——	——	——
Other accrued liabilities	$238K—	$181K—	$120K—	$142K—	——
Other commitment, liability, refundable deposit, amount	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$0—	$0—	$0—	$0—	——
Preferred Stock, Shares Authorized	$10M—	$10M—	$10M—	$10M—	——
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	——
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	——
Registration Payment Arrangement Maximum Potential Consideration	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$11.87M—	$9.85M—	$9.16M—	$8.8M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$10.74—	$9.03—	$7.69—	$7.56—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Bicara Therapeutics cover its short-term obligations?: Its current ratio is 13.85 — current assets exceed current liabilities.
Where does Bicara Therapeutics's balance sheet data come from?: Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.